Angiogenic gene therapy does not cause retinal pathology
- 1 September 2014
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 16 (9-10) , 309-316
Abstract
Background The potential negative influence of angiogenic gene therapy on the development or progression of retinal pathologies such as diabetic retinopathy (DR) or age‐related macular degeneration (AMD) has led to the systematic exclusion of affected patients from trials. We investigated the role of nonviral fibroblast factor 1 (NV1FGF) in two phase II, multinational, double‐blind, randomized, placebo‐controlled, gene therapy trials (TALISMAN 201 and 211). Methods One hundred and fifty‐two subjects with critical limb ischemia or claudication were randomized to receive eight intramuscular injections of 2.5 ml of NV1FGF at 0.2 mg/ml or 0.4 mg/dl or placebo. One hundred and fifty‐two patients received a plasmid dose of NV1FGF of up to 32 mg or placebo. All patients underwent a systematic ophthalmologic examination at baseline and at 3, 6 or 12 months following gene therapy. Twenty‐six of these patients (Münster subgroup) received a retinal fluorescence angiography at baseline and at final examination. Results Among those 26 patients, four of nine patients with diabetes suffered from nonproliferative DR. Three patients showed non‐exsudative AMD. No change of retinal morphology or function was observed in Münster subgroup of both TALISMAN trials independent of the intramuscular NV1FGF dosage applied. Conclusions Angiogenic gene therapy using NV1FGF is safe even in diabetics. Copyright © 2014 John Wiley & Sons, Ltd.Keywords
This publication has 41 references indexed in Scilit:
- Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery diseaseGene Therapy, 2011
- Changes in Incidence of Diabetes Mellitus–Related Eye Disease Among US Elderly Persons, 1994-2005Archives of Ophthalmology (1950), 2008
- Vascular endothelial growth factor in eye diseaseProgress in Retinal and Eye Research, 2008
- Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatmentGene Therapy, 2006
- Direct intramyocardial plasmid vascular endothelial growth factor-A165gene therapy in patients with stable severe angina pectorisJACC, 2005
- Safety Evaluation of Clinical Gene Therapy Using Hepatocyte Growth Factor to Treat Peripheral Arterial DiseaseHypertension, 2004
- Adenovirus-Mediated Acidic Fibroblast Growth Factor Gene Transfer Induces Angiogenesis in the Nonischemic Rabbit HeartMicrovascular Research, 1999
- Effect of Basic Fibroblast Growth Factor on Myocardial Angiogenesis in Dogs With Mature Collateral VesselsJACC, 1997
- Importance of Fluorescein Angiography in the Early Detection and Therapy of Diabetic RetinopathyOphthalmologica, 1990
- A Method of Photographing Fluorescence in Circulating Blood in the Human RetinaCirculation, 1961